Odevixibat (A4250) 是一种有效的选择性回肠胆汁酸转运蛋白 (IBAT) 抑制剂。Odevixibat (A4250) 可减轻小鼠模型中的胆汁淤积性肝和胆管损伤。Odevixibat (A4250)可用于原发性胆汁性肝硬化的研究。

Odevixibat is an effective, selective and orally active ileal bile acid transporter inhibitor. Odevixibat has the potential for the treatment of primary biliary cirrhosis. Odevixibat reduces cholestatic liver and bile duct injury in mice model.

Odevixibat obviously decreases bile flow and biliary BA output, which correlates with reduced bsep transcription, while Ntcp and Cyp7a1 are induced. Odevixibat (0.01% (w/w) in chow diet; 4 weeks) improves sclerosing cholangitis and significantly decreases serum alanine aminotransferase, alkaline phosphatase and BAs levels, hepatic expression of pro-inflammatory and pro-fibrogenic genes and bile duct proliferation in Mdr2-/- mice [1].

501692-44-0

C37H48N4O8S2

740.93

A4250;Odevixibat

DMSO:150.0 mg/mL (202.5 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years